Persistent Coronavirus Disease 2019 (COVID-19) in an Immunocompromised Host Treated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Monoclonal Antibodies.

Authors :: Bailly B
Péré H
Veyer D
Berceanu A
Daguindau E
Roux P
Hermine O
de Lamballerie X
Bastard P
Lacombe K
Autran B
Angelot Delettre F
Laurent Casanova J
Imbeaud S
Laure Clairet A
Kroemer M
Spehner L
Robillard N
Puech J
Marty-Quinternet S
Lepiller Q
Chirouze C
Bouiller K
Source :: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2022 May 03; Vol. 74 (9), pp. 1706-1707.
Publication Year :: 2022

Subjects :: Antibodies, Monoclonal therapeutic use
Antibodies, Viral
Humans
Immunocompromised Host
COVID-19
SARS-CoV-2

Language :: English
ISSN :: 1537-6591
Volume :: 74
Issue :: 9
Database :: MEDLINE
Journal :: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Publication Type :: Editorial & Opinion
Accession number :: 34598278
Full Text :: https://doi.org/10.1093/cid/ciab868

Full Text Access

Tools